Whitepapers

Bio-Rad Laboratories, Inc., Pioneer™ Antibody Discovery Platform helps streamline the phage display-based discovery process and provides researchers with superior identification of high-quality therapeutic antibodies.

Advancements in isothermal amplification technologies are fueling new diagnostic and clinical approaches for pathogen detection and cancer research.

As today’s labs continue to evolve, the software solutions that support them must too. Likewise, laboratory and organization leadership must be open to the advancements available to them from modern technologies. In this white paper, learn how a SaaS-based LIMS modernization program optimizes data management, fosters collaboration, and improves decision-making to stay at the forefront of scientific innovation.

Innovation is the engine that powers a company’s growth and product development, and for enterprises with R&D laboratories, those lab environments are the greatest source of this innovation. In this white paper, learn how a platform approach to scientific data management, including semantic search, advanced analytics, and lab automation, leads to better enterprise decisions at the executive level, optimized lab performance, more discoveries, and stronger product pipelines.

Biopharmaceutical companies are increasingly partnering with CDMOs equipped with technologies and expertise to support analytical testing during process development. The level of complexity required to develop and manufacture cell and gene therapies has increased, including the use of various raw materials, custom reagents, and tailored approaches for managing complex diseases.

Charge heterogeneity is present in most biopharmaceutical protein products. During the manufacturing process, charge heterogeneity of the protein therapeutics can occur due to enzymatic cleavage and chemical post-translational modifications (PTM). For therapeutics like ADCs, not only the antibody contributes to the heterogeneity but also the linker and payload, which add even more complexity to the charge variant profiles. Characterizing the charge heterogeneity of ADCs is essential for critical quality attribute (CQA) assessment to ensure drug safety, efficacy, and potency.

Experience flexibility with TaqMan assays, offering over 2.8 million predesigned options to meet your specific needs.

An intelligent, on-premise platform connecting all the steps of your post-discovery routine qPCR workflows into one single ecosystem. Contact sales for a demo

TaqMan SNP Genotyping Assays help you detect and distinguish single-nucleotide polymorphisms (SNPs) accurately and efficiently.

Multiplex better with the newest additions to the TaqMan portfolio

Partnering with a CDMO can help streamline drug development, and certain preparations can help ensure a successful collaboration. Scott Alderucci, Curia’s Director of Process Development, explores the advantages of partnering with a CDMO to navigate the journey from molecule conception to clinical trials, including the expertise, experience, and preparedness that a CDMO brings to the table.

Discover how to accurately analyze purity and impurities, determine sequences, and more with next-generation technologies from Agilent.

Key strategies for accelerating development and manufacturing and development timelines to bring drugs to market faster and give developers a competitive advantage.

Now supplying cleanroom doors, panels and accessories for all cleanroom applications.

The first of its kind prefabricated cleanroom system that integrates with the host facility floor.

Implementing automation involves careful optimization and fine-tuning of various parameters to ensure the accurate execution of cell-based potency assays.

G-CON Clean Solutions has a best in class offering of cleanroom doors, panels and accessories for all cleanroom applications.

A step-by-step path to building confidence in packaging component selection for injectable drugs

Ensure the success of clinical biomanufacturing programs by focusing on key tech transfer practices from the sponsor, commercial, scientific, and program management stakeholders.

Partnering with a CDMO with collective insights and capabilities to support the development and manufacture of an innovative biotherapeutic program is an essential first step to providing better care to patients.

As pipettes touch virtually every experiment, they influence the accuracy and repeatability of the experimental data.

This application note presents a protocol for Sf9 insect cell culture in stirred-tank bioreactors and recombinant protein production via a baculovirus vector system.